REG - ReNeuron Group plc - Directors' Interest in Shares and Share Options <Origin Href="QuoteRef">RQE.L</Origin>

ReNeuronAnnouncement

12/09/2017 07:07

RNS Number : 4642Q
ReNeuron Group plc
12 September 2017
12 September 2017
AIM: RENE
ReNeuron Group plc
Directors' Interest in Shares and Share Options 
ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that on 11 September 2017, the following awards were made under the Company's share-based incentive plans:
1. Long Term Incentive Plan (LTIP)

Number of LTIP share options granted






Olav Helleb 
 9,766,667


Michael Hunt
 6,800,000






The LTIP awards are share options granted at nominal value and are subject to a three-year holding period, exercisable from the third anniversary of the award. The options are exercisable subject to the achievement of the following performance conditions:
1) When the first patientisadministered with a ReNeuron cell therapy in an eighth clinical trial, one third of the options will vest. 
2) When the sixth clinical trial of a ReNeuron cell therapy completes, one third of the options will vest.
3) If the Total Shareholder Return (TSR) of the Companymeets or exceeds that of the FTSE AIM Healthcare Indexin any given three year period from the date of grant, one third of the options will vest. 
After the above share option grants, the executive directors of the Company have the following share option holdings: 





Total shares over which options are held 
Percentage of issued shares under option





Olav Helleb 
65,012,526
2.05%

Michael Hunt
37,476,902
1.18%

2. Non-Executive Share Option Scheme

Number of shares awarded
Total shares over which options are held 





John Berriman
500,000
3,055,322

Simon Cartmell
500,000
3,055,322

Tim Corn
500,000
2,375,249

Claudia D'Augusta 500,000  500,000
Chris Evans  500,000  1,800,000
Mike Owen  500,000  800,000
The Non-Executive Directors of the Company are remunerated partly in cash and partly in the form of share options granted under the Non-Executive Share Option Scheme. In order to remove as far as possible any incentive element that might influence the Non-Executive Directors' independence, share options are granted under the Non-Executive Share Option Scheme at nominal value without performance conditions attaching and vest over three years on a straight line basis. 
ENDS
ENQUIRIES:
ReNeuron
+44 (0)20 3819 8400
Olav Helleb , Chief Executive Officer

Michael Hunt, Chief Financial Officer

Buchanan
+44 (0) 20 7466 5000
Mark Court, Sophie Cowles, Stephanie Watson



Stifel Nicolaus Europe Limited
+44 (0) 20 7710 7600
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)

Nplus1 Singer Advisory LLP
+44 (0) 20 7496 3000
Mark Taylor (Joint Broker)

About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need. 
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa. 
ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise lack adequate capacity to penetrate to their site of action.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCELLBFDKFLBBX